Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H15N3O4 |
| Molecular Weight | 217.2227 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O
InChI
InChIKey=HJCMDXDYPOUFDY-WHFBIAKZSA-N
InChI=1S/C8H15N3O4/c1-4(9)7(13)11-5(8(14)15)2-3-6(10)12/h4-5H,2-3,9H2,1H3,(H2,10,12)(H,11,13)(H,14,15)/t4-,5-/m0/s1
| Molecular Formula | C8H15N3O4 |
| Molecular Weight | 217.2227 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.rlsnet.ru/prep_index_id_43164.htmCurator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02053350 | https://www.ncbi.nlm.nih.gov/pubmed/26518955 | https://clinicaltrials.gov/ct2/show/NCT01832636 | https://www.ncbi.nlm.nih.gov/pubmed/22986234
Sources: https://www.rlsnet.ru/prep_index_id_43164.htm
Curator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02053350 | https://www.ncbi.nlm.nih.gov/pubmed/26518955 | https://clinicaltrials.gov/ct2/show/NCT01832636 | https://www.ncbi.nlm.nih.gov/pubmed/22986234
Alanyl-glutamine is a widely used alternative supplement to L-glutamine in the production of biopharmaceuticals. The primary advantage of using L-alanyl-glutamine in place of L-glutamine is that it reduces the level of ammonia generated during cell culture. L-alanyl glutamine also acts as an antioxidant (peroxide) and anti-apoptosis (LPS-induced) factor. Ala-Glu may be used in cell culture and insect cell culture applications. It can be used in studies on injury and sepsis, and in the effects of irradiation on leucine and protein metabolism in vivo. Alanyl-glutamine is used as dipeptide infusion solution, which is given as part of parenteral and/or enteral nutritional therapy. When the intake of nutrients or food into the mouth or directly into the gut is not possible or it is not enough to supply the body’s needs then nutrients or foods can be given intravenously or through the gastrointestinal tract or a combination of both. This is especially important for people whose bodies are under physical stress from illness or recent surgery. During illness or after surgery the body requires nutrition or food. Amino acids are the building blocks used by the body to make proteins. Dipeptiven is usually given as a supplement to amino acid solutions or an amino acid containing infusion regimen as part of complete nutritional support.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
652 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16049639/ |
0.5 g/kg 1 times / day steady-state, intravenous dose: 0.5 g/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
ALANYL GLUTAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.26 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16049639/ |
0.5 g/kg 1 times / day steady-state, intravenous dose: 0.5 g/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
ALANYL GLUTAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Metabolic changes induced by pre-administration of L-alanyl-glutamine and omega-3 in Wistar rats subjected to sepsis. | 2010-12 |
|
| Randomized clinical trial of gut-specific nutrients in critically ill surgical patients. | 2010-11 |
|
| Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. | 2010-10-04 |
|
| Effects of in ovo injecting disaccharides and alanyl-glutamine dipeptide on the energy status in duck embryos and neonates. | 2010-10 |
|
| The impact of glutamine dipeptide-supplemented parenteral nutrition on outcomes of surgical patients: a meta-analysis of randomized clinical trials. | 2010-09-21 |
|
| Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. | 2010-08-11 |
|
| Glutamate exocrine dynamics augmented by plasma glutamine and the distribution of amino acid transporters of the rat pancreas. | 2010-06 |
|
| L-alanyl-glutamine preoperative infusion in patients with critical limb ischemia subjected to distal revascularization reduces tissue damage and protects from oxidative stress. | 2010-05 |
|
| Parenteral nutrition: Revisited. | 2010-03 |
|
| Effect of multidrug-efflux transporter genes on dipeptide resistance and overproduction in Escherichia coli. | 2010-03 |
|
| Examination of the efficacy of acute L-alanyl-L-glutamine ingestion during hydration stress in endurance exercise. | 2010-02-03 |
|
| Effects of supplementation with free glutamine and the dipeptide alanyl-glutamine on parameters of muscle damage and inflammation in rats submitted to prolonged exercise. | 2010-01 |
|
| Glutamine and alanyl-glutamine dipeptide reduce mesenteric plasma extravasation, leukocyte adhesion and tumor necrosis factor-α (TNF-α) release during experimental endotoxemia. | 2009-12 |
|
| Nutrition support with glutamine dipeptide in patients undergoing liver transplantation. | 2009-12 |
|
| Surgery and transplantation - Guidelines on Parenteral Nutrition, Chapter 18. | 2009-11-18 |
|
| Amino acids - Guidelines on Parenteral Nutrition, Chapter 4. | 2009-11-18 |
|
| Clinical trial: prophylactic intravenous alanyl-glutamine reduces the severity of gastrointestinal toxicity induced by chemotherapy--a randomized crossover study. | 2009-09-01 |
|
| Modulation of B-cell endoplasmic reticulum calcium homeostasis by Epstein-Barr virus latent membrane protein-1. | 2009-08-03 |
|
| The effect of intravenous alanyl-glutamine supplementation on plasma glutathione levels in intensive care unit trauma patients receiving enteral nutrition: the results of a randomized controlled trial. | 2009-08 |
|
| Protective effects of glutamine dipeptide and alpha-tocopherol against ischemia-reperfusion injury in the isolated rat liver. | 2009-06 |
|
| L-Glutamine or L-alanyl-L-glutamine prevents oxidant- or endotoxin-induced death of neonatal enterocytes. | 2009-05 |
|
| Amino acids change liver growth factors gene expression in malnourished rats. | 2009-04-08 |
|
| Effects of oral supplementation with glutamine and alanyl-glutamine on glutamine, glutamate, and glutathione status in trained rats and subjected to long-duration exercise. | 2009-04 |
|
| Perioperative application of L-alanyl-L-glutamine in cardiac surgery: effect on the polarized T cell cytokine expression. | 2009-03 |
|
| Intravenous glutamine decreases lung and distal organ injury in an experimental model of abdominal sepsis. | 2009 |
|
| Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. | 2008-12-20 |
|
| Protective effects of alanyl-glutamine on acute lung injury induced by lipopolysaccharide in rats. | 2008-12 |
|
| Alanyl-glutamine and glutamine supplementation improves 5-fluorouracil-induced intestinal epithelium damage in vitro. | 2008-10 |
|
| L-alanyl-L-glutamine-supplemented parenteral nutrition decreases infectious morbidity rate in patients with severe acute pancreatitis. | 2008-07-04 |
|
| Efficacy of parenteral nutrition supplemented with glutamine dipeptide to decrease hospital infections in critically ill surgical patients. | 2008-07-04 |
|
| Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation. | 2008-06 |
|
| Hartree-Fock calculations with linearly scaling memory usage. | 2008-05-14 |
|
| Metabolic effects of enteral versus parenteral alanyl-glutamine dipeptide administration in critically ill patients receiving enteral feeding: a pilot study. | 2008-04 |
|
| Safety studies of l-alanyl-l-glutamine (l-AG). | 2008-03 |
|
| Year in review in Intensive Care Medicine, 2007. I. Experimental studies. Clinical studies: brain injury and neurology, renal failure and endocrinology. | 2008-02 |
|
| Frequent intravenous pulses of growth hormone together with alanylglutamine supplementation in prolonged critical illness after multiple trauma: effects on glucose control, plasma IGF-I and glutamine. | 2008-02 |
|
| Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster. | 2008-02 |
|
| Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage. | 2008-01-21 |
|
| [Effect of glutamine on serum interleukin-8 and tumor necrosis factor-alpha levels in patients with severe pancreatitis]. | 2008-01 |
|
| Depletion of plasma antioxidants in surgical intensive care unit patients requiring parenteral feeding: effects of parenteral nutrition with or without alanyl-glutamine dipeptide supplementation. | 2008-01 |
|
| [Objectivization of the diagnostics and control of treatment of paresis of the gastrointestinal tract in diffuse peritonitis]. | 2008 |
|
| L-alanine-L-glutamine supplementation improves the outcome after colorectal surgery for cancer. | 2007-11 |
|
| Short-term alanyl-glutamine dipeptide pretreatment in liver ischemia-reperfusion model: effects on microcirculation and antioxidant status in rats. | 2007-10 |
|
| Specific amino acids in the critically ill patient--exogenous glutamine/arginine: a common denominator? | 2007-09 |
|
| [Effect of early enriched parenteral alanyl-glutamine on heat shock protein 70 (HSP70) expression in critical patients]. | 2007-08 |
|
| L-alanin-L-glutamine supplementation improves the outcome after colorectal surgery for cancer. | 2007-07 |
|
| A controlled trial of glutamine effects on bone healing. | 2007-05-29 |
|
| Glutamine kinetics during intravenous glutamine supplementation in ICU patients on continuous renal replacement therapy. | 2007-04 |
|
| Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral formula. | 2007-03 |
|
| Glutamine induces heat-shock protein and protects against Escherichia coli lipopolysaccharide-induced vascular hyporeactivity in rats. | 2007 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01832636
Alanyl-Glutamine orally 3g/day for 10 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22986234
IEC-6 cells were seeded in 12-well plates in a concentration of 6.25 Ч 104 cells/well and cultivated in DMEM media with 5% FCS (Gibco BRL). IEC-6 cells were confluent after 2 d following seeding. In order to rule out the effect of cell proliferation on cell migration, wells were incubated for 20 min with 5 μg/mL of mitomycin C, which inhibits DNA synthesis and cell mitosis. Wells were then scratched along their diameter and extended 30 mm in length to the right center corner, using a sterile razor blade. Prior to scratching, 50% of the media volume was removed from each study well. The media was changed and the cells were then incubated in DMEM media without glutamine (Gln) with 0, 7, 10, 70 and 100 μg/mL of NFV, diluted in 0.5% DMSO. After one hour of incubation, wells were washed using DMEM media without Gln and incubated with DMEM media without Gln for 12 or 24 h. To evaluate the effect of AQ (Alanyl-glutamine) on cell migration, after incubating the wells with mitomycin C for 20 min and scratching, the wells were incubated with either DMEM media without Gln or DMEM media without Gln supplemented with 1, 5, 10 or 50 mM of AQ.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:11:40 GMT 2025
by
admin
on
Mon Mar 31 19:11:40 GMT 2025
|
| Record UNII |
U5JDO2770Z
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
B05XB02
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
||
|
WHO-VATC |
QB05XB02
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
||
|
FDA ORPHAN DRUG |
611617
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
||
|
DSLD |
3081 (Number of products:109)
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
||
|
JECFA EVALUATION |
L-ALANYL-L-GLUTAMINE
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
39537-23-0
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
74387
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
U5JDO2770Z
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
2098
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
100000127872
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL3707366
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
123935
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
DTXSID20192658
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
DB11876
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
73788
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
Alanyl-glutamine
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
C127908
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
U5JDO2770Z
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
1359422
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | RxNorm | ||
|
C1505
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
1012517
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
4319
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY | |||
|
SUB34011
Created by
admin on Mon Mar 31 19:11:40 GMT 2025 , Edited by admin on Mon Mar 31 19:11:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|